WUNDERKIND
21.5.2024 15:01:26 CEST | Business Wire | Press release
Wunderkind, the leading AI-driven performance marketing solution, today announced the launch of its AI-powered Autonomous Marketing Platform and its first application, Studio, which brings self-service tools to the creative workflow for marketers and services teams.
Wunderkind’s Autonomous Marketing Platform leverages the power of artificial intelligence (AI) to streamline the entire marketing build, report and optimisation process. Through the analysis of trillions of behavioural data points, the platform uncovers valuable insights, facilitating the creation and execution of strategies that drive undeniable performance. The Wunderkind platform delivers on marketing use cases, such as making actionable data available through identity, leveraging AI to deliver omnichannel experiences, measuring insights and integrating with the broader martech ecosystem.
The Autonomous Marketing Platform is underpinned by the Wunderkind Identity Network, a proprietary Identity graph which recognises over 9 billion consumer devices, 1 billion opted-in consumer profiles and observes 2 trillion events per year. This allows Wunderkind to identify up to 50% more consumer profiles than leading email service providers (ESPs), enabling its AI-powered marketing engine to deliver significantly more personalised, 1:1 emails and text messages to drive ROI.
Studio, the First Application in the Platform Roadmap
As the critical marketing infrastructure for more than 700 brands and retailers, Wunderkind’s Studio streamlines the design process to create best-in-class brand experiences for the entire creative process. Studio provides the ability to make real-time creative edits to experiences, which is improving the time to build and launch campaigns by over 50% for Wunderkind clients. The Generative AI (Gen AI) capabilities in Studio empower marketers to quickly optimise their messaging, ensuring optimal conversions based on Wunderkind’s observation across trillions of consumer interactions.
Studio represents a watershed moment for Wunderkind, marking a significant evolution in its AI-driven product vision, which centres on providing adaptive learning and decisioning to proactively elevate marketing performance. Wunderkind’s roadmap includes additional AI-powered applications to further optimise the creation of bespoke customer experiences, robust audience development and deep analytics on engagement and revenue attribution.
This investment in the platform and its connected applications complements Wunderkind’s award-winning managed service offering, which delivers more than $5 billion in guaranteed revenue every year for brands such as Uniqlo, Sonos, Clarks and Kurt Geiger, and typically generates more than 10% of total digital revenue for clients.
“Our Autonomous Marketing Platform brings the full potential of our proprietary data and best practices to scale through AI,” Bill Ingram, CEO at Wunderkind, commented. “Studio significantly reduces the time spent on building marketing creatives and elevating outstanding performance. Wunderkind’s continued investments in AI allows us to deliver dynamic consumer experiences, which drive revenue while guiding brands through massive industry changes.”
Molly Delp, VP of eCommerce and Digital Marketing at skincare brand True Botanicals, commented: “We love Wunderkind because it's a managed service that lets us focus on our day-to-day while their professional services team delivers the engagement and eCommerce revenue lift we need. The launch of Studio brings speed and agility to our revenue strategy”.
Wunderkind will host a virtual public roadmap event on 26 June 2024, which will provide further details on its Autonomous Marketing Platform and other forthcoming applications planned to help marketers drive further enhanced performance and ROI. To register, sign up here.
Notes to editors
About Wunderkind
Wunderkind is the leading AI-driven performance marketing solution that collects consent-based, first-party data and identifies anonymous traffic for brands in order to scale hyper-personalised one-to-one messages. Brands lean on the Wunderkind Identity Network, a proprietary database recognising 9 billion devices and 1 billion opted-in consumers, observing 2 trillion digital transactions per year, to trigger the most impactful offers to their target audience at the right moment and in the right channel. This proprietary data is accessed by Wunderkind's autonomous AI engine, which integrates seamlessly into a brand's existing ESP, to boost performance across email, text and advertising channels.
Wunderkind is the only performance solution that guarantees a lift in revenue for its clients and delivers over $5 billion in directly attributable revenue annually for brands across a number of industries, often ranking as a top 3 revenue channel in clients' own analytics platforms. Brands such as Harley-Davidson, Perry Ellis and Shoe Carnival partner with Wunderkind to drive top-line revenue through its guaranteed results. To learn more, visit wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521214381/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom